0000899243-19-016474.txt : 20190611 0000899243-19-016474.hdr.sgml : 20190611 20190611183149 ACCESSION NUMBER: 0000899243-19-016474 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190607 FILED AS OF DATE: 20190611 DATE AS OF CHANGE: 20190611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BREITMEYER JAMES B CENTRAL INDEX KEY: 0001244823 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 19892094 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GTX INC /DE/ CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17 W PONTOTOC AVE. STREET 2: SUITE 100 CITY: MEMPHIS STATE: TN ZIP: 38103 BUSINESS PHONE: 901-523-9700 MAIL ADDRESS: STREET 1: 17 W PONTOTOC AVE. STREET 2: SUITE 100 CITY: MEMPHIS STATE: TN ZIP: 38103 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-07 0 0001260990 GTX INC /DE/ ONCT 0001244823 BREITMEYER JAMES B C/O ONCTERNAL THERAPEUTICS, INC. 12230 EL CAMINO REAL, SUITE 300 SAN DIEGO CA 92130 1 1 0 0 President, CEO Common Stock 2019-06-07 4 A 0 255591 A 255591 D Common Stock 2019-06-07 4 A 0 733 A 733 I By child. Common Stock 2019-06-07 4 A 0 21544 A 21544 I By family trust. Stock Options 0.68 2019-06-07 4 A 0 117417 A 2025-08-30 Common Stock 117417 117417 D Stock Options 0.68 2019-06-07 4 A 0 1467 A 2027-04-12 Common Stock 1467 1467 I By spouse. Warrants 6.13 2019-06-07 4 A 0 733 A 2022-09-12 Common Stock 733 733 I By family trust. Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share. The option is currently vested with respect to 110,079 shares. The remaining shares subject to the option will vest in three equal monthly installments beginning on June 30, 2019. The option is currently vested with respect to 826 shares. The remaining shares subject to the option will vest in equal monthly installments until February 1, 2021. The warrants are currently exercisable. /s/ Hazel M. Aker, Attorney-in-fact 2019-06-11